<DOC>
	<DOCNO>NCT00583778</DOCNO>
	<brief_summary>This double blind , control clinical trail test whether three dos 1.25 mg nebulized levalbuterol combination three dose 0.5mg nebulized ipratropium lead great bronchodilation achieve three dos nebulized 1.25 mg levalbuterol alone every 20 minute . The primary hypothesis study three dose 1.25 mg nebulized levalbuterol combination three dose 0.5mg nebulized ipratropium lead great bronchodilation achieve three dos nebulized 1.25 mg levalbuterol alone every 20 minute . The secondary hypothesis treatment combination levalbuterol ipratropium lead few hospitalization levalbuterol alone patient acute asthma exacerbation . Other secondary objective include ( 1 ) evaluate relationship baseline ( S ) - albuterol level ( R ) - albuterol level presentation FEV1 , ( 2 ) relationship baseline ( S ) - albuterol level ( R ) - albuterol level presentation change FEV1 , ( 3 ) time event analysis improvement 15 % , 20 % , 30 % , 40 % , 50 % FEV1 initial presentation value , ( 4 ) analysis FEV1 discharge .</brief_summary>
	<brief_title>A Comparison Levalbuterol Plus Ipratropium With Levalbuterol Alone Treatment Acute Asthma Exacerbation</brief_title>
	<detailed_description>Patients receive , randomize double-blinded fashion , levalbuterol , 1.25mg every 20 minute total 3 aerosolized dos combine ipratropium , 0.5mg every 20 minute total 3 aerosolized dos . The medication premixed pharmacy total 3 ml normal saline nebulizer drive oxygen 6 liter per minute . A second plasma sample analysis albuterol isomer draw within fifteen minute window follow third aerosol treatment . Spirometry repeat 30 60 minute third aerosol treatment ( Figure 1 ) . All patient receive prednisone , 60mg orally immediately first dose aerosolized medication , unless contraindication prednisone administration present . Patients receive medication time course study . Vital sign pulse oximetry repeat prior nebulized treatment 30 minute third nebulized treatment . The study terminate 60 minute third aerosol administration . At point , therapy discretion treat physician . Patients question occurrence side effect levalbuterol treatment include palpitation , anxiety , nausea , vomit headache . Patients also question occurrence side effect ipratropium , include dry mouth , dry eye , urinary retention . Patients withdraw study point side effect become intolerable patient time patient desire . Patients also withdraw develop palpitation ECG demonstrate ventricular supraventricular tachycardia . .Patients call 14 day ED visit ass relapse recurrence acute asthma exacerbation . In addition , chart review perform assess relapse recurrence acute asthma exacerbation , well determine hospital length stay patient require admission initial visit .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>1845 year age history asthma FEV1 &gt; 50 % predict height , age , gender race upon presentation ED cause wheeze shortness breath except asthma determine Investigator history glaucoma Ipratropium anticholinergic within 6 hour study subject , investigator 's opinion , lifethreatening asthma require emergent intervention preclude ability complete treatment treatment period base upon history physical exam ED orClinic , subject know suspected cause pulmonary symptom asthma , COPD , CHF , pneumonia , pulmonary embolism , angioedema subject know sensitivity levalbuterol racemic albuterol know 20 pack year smoker use ipratropium 6 hour prior present ED subject may pregnant pregnant e evidence pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Bronchodilators</keyword>
	<keyword>Levalbuterol</keyword>
	<keyword>Ipratropium</keyword>
</DOC>